The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous system leading to destruction of myelin sheaths. Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin which has been approved for treatment of relapsing forms of MS. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazdeh, Mehrdokht, Hosseini, Shno, Taheri, Mohammad, Ghafouri-Fard, Soudeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265353/
https://www.ncbi.nlm.nih.gov/pubmed/30498920
http://dx.doi.org/10.1186/s40169-018-0216-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265353/
https://www.ncbi.nlm.nih.gov/pubmed/30498920
http://dx.doi.org/10.1186/s40169-018-0216-3

Ejemplares similares